DE69609314T2 - Amorph piretanide, polymorphe davon, verfahren zur dessen herstellung und ihre verwendung - Google Patents

Amorph piretanide, polymorphe davon, verfahren zur dessen herstellung und ihre verwendung

Info

Publication number
DE69609314T2
DE69609314T2 DE69609314T DE69609314T DE69609314T2 DE 69609314 T2 DE69609314 T2 DE 69609314T2 DE 69609314 T DE69609314 T DE 69609314T DE 69609314 T DE69609314 T DE 69609314T DE 69609314 T2 DE69609314 T2 DE 69609314T2
Authority
DE
Germany
Prior art keywords
pct
sec
peak
piretanide
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69609314T
Other languages
English (en)
Other versions
DE69609314D1 (de
Inventor
Yuji Chikaraishi
Yoshihisa Matsuda
Makoto Otsuka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis UK Holdings Ltd
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP03321595A external-priority patent/JP3532987B2/ja
Priority claimed from JP03321695A external-priority patent/JP3532988B2/ja
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Application granted granted Critical
Publication of DE69609314D1 publication Critical patent/DE69609314D1/de
Publication of DE69609314T2 publication Critical patent/DE69609314T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Glass Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69609314T 1995-02-22 1996-02-12 Amorph piretanide, polymorphe davon, verfahren zur dessen herstellung und ihre verwendung Expired - Lifetime DE69609314T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP03321595A JP3532987B2 (ja) 1995-02-22 1995-02-22 新規な無晶形ピレタニドおよびその製造方法
JP03321695A JP3532988B2 (ja) 1995-02-22 1995-02-22 ピレタニドの新規な結晶多形およびその製造方法
PCT/IB1996/000254 WO1996026197A1 (en) 1995-02-22 1996-02-12 Amorphous piretanide, piretanide polymorphs, process for their preparation and their use

Publications (2)

Publication Number Publication Date
DE69609314D1 DE69609314D1 (de) 2000-08-17
DE69609314T2 true DE69609314T2 (de) 2001-06-13

Family

ID=26371876

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69609314T Expired - Lifetime DE69609314T2 (de) 1995-02-22 1996-02-12 Amorph piretanide, polymorphe davon, verfahren zur dessen herstellung und ihre verwendung

Country Status (15)

Country Link
US (1) US6096779A (de)
EP (1) EP0812320B1 (de)
KR (1) KR100419355B1 (de)
CN (1) CN1072215C (de)
AT (1) ATE194607T1 (de)
BR (1) BR9607295A (de)
CA (1) CA2213693C (de)
DE (1) DE69609314T2 (de)
DK (1) DK0812320T3 (de)
ES (1) ES2150105T3 (de)
GR (1) GR3034605T3 (de)
HK (1) HK1006783A1 (de)
MX (1) MX9706339A (de)
PT (1) PT812320E (de)
WO (1) WO1996026197A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW526195B (en) 1997-06-10 2003-04-01 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
HRP20000162B1 (en) * 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
DK1567529T4 (da) 2002-05-16 2021-05-10 Janssen Sciences Ireland Uc Pseudopolymorfe former af en hiv-proteaseinhibitor
EA011862B1 (ru) * 2004-03-24 2009-06-30 Актавис Груп Хф. Композиции рамиприла
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2419970C3 (de) * 1974-04-25 1980-06-12 Hoechst Ag, 6000 Frankfurt 3-<l-Pyrrolidinyl)-4-phenoxy-5sulfamoylbenzoesäure und Verfahren zu ihrer Herstellung
JPS5283547A (en) * 1976-01-01 1977-07-12 Hoechst Ag Tertiary cyclic amine
DE2655331A1 (de) * 1976-12-07 1978-06-08 Hoechst Ag Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung
EP0243891B1 (de) * 1986-04-29 1991-08-14 Hoechst-Roussel Pharmaceuticals Incorporated Schichtenstruktur für die Verabreichung von Chemikalien mit kontrollierter Abgaberate
EP0465841A3 (en) * 1990-06-13 1992-10-14 Hoechst Aktiengesellschaft Quick acting pharmaceutical inhalation forms of diuretics
JPH05230044A (ja) * 1992-02-21 1993-09-07 Hoechst Japan Ltd ピレタニドの新規な結晶多形

Also Published As

Publication number Publication date
GR3034605T3 (en) 2001-01-31
HK1006783A1 (en) 1999-03-19
PT812320E (pt) 2000-12-29
DK0812320T3 (da) 2003-04-14
EP0812320B1 (de) 2000-07-12
CN1175948A (zh) 1998-03-11
MX9706339A (es) 1998-07-31
KR19980702374A (ko) 1998-07-15
WO1996026197A1 (en) 1996-08-29
ES2150105T3 (es) 2000-11-16
EP0812320A1 (de) 1997-12-17
ATE194607T1 (de) 2000-07-15
CA2213693C (en) 2008-04-15
KR100419355B1 (ko) 2004-06-04
BR9607295A (pt) 1997-11-25
US6096779A (en) 2000-08-01
CN1072215C (zh) 2001-10-03
DE69609314D1 (de) 2000-08-17
CA2213693A1 (en) 1996-08-29

Similar Documents

Publication Publication Date Title
DE69429078T2 (de) Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
BG104561A (en) Aryl fused azapolycyclic compounds
YU43694A (sh) Magnezijum omeprazol i postupak za dobijanje ovog jedinjenja
DE69706566D1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
ATE182333T1 (de) Heterocyclische verbindungen, ihre herstellung und verwendung
ATE94869T1 (de) Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika.
DE69727806D1 (de) 1,2,4-benzothiadiazin-derivate, ihre herstellung und verwendung
DE69609314T2 (de) Amorph piretanide, polymorphe davon, verfahren zur dessen herstellung und ihre verwendung
DE69813565D1 (de) Substituierte 3,3-diamino-2-propennitrile, ihre herstellung und verwendung
DE69510212D1 (de) Colchicin-derivate sowie ihre therapeutische verwendung
HU9602413D0 (en) Novel tetrasubstituted imidazole derivatives, method for preparing same, resulting novel intermediates, use thereof as drugs, and pharmaceutical compositions containing same
ATE85334T1 (de) Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung.
NO975921D0 (no) Fremstilling av bicykloheksanderivater
ATE181832T1 (de) Pyrido-pyrimidindione, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69514532T2 (de) Indol-2,3-dione-3-oximderivate, ihre herstellung und verwendung
HUT77768A (hu) N-szubsztituált azabicikloheptánszármazékok, eljárás előállításukra és alkalmazásuk
ATE205473T1 (de) Neue borneolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
ATE186640T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen
DE69424415D1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
DE68906647D1 (de) Hydroxy-1,2,3,4-tetrahydroaminoacridine, verfahren fuer ihre herstellung und ihre verwendung als arzneimittel.
DE69609541D1 (de) Verwendung von 6,7-substituierten-2-Aminotetraline zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von septischem Schock, und antipyretischer und antientzündlicher Zusammensetzungen
ATE87002T1 (de) Substituierte 3-phenyl-7h-thiazolo(3,2 -b&gt; (1,2,4&gt;triazin-7-one, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung, sowie einige bei der herstellung der genannten verbindungen gebildete zwischenprodukte.
DE69917440D1 (de) 5-imino-13-deoxy-antracyclin-derivate, ihre verwendung sowie verfahren zu deren herstellung
AU2796695A (en) Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders
DE3767504D1 (de) Tetrahydrobenz(c,d)indol-derivate, ihre salze, verfahren zur herstellung, verwendung als arzneimittel, ihre zusammensetzungen und zwischenprodukte.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS PHARMA LTD., TOKIO/TOKYO, JP

8364 No opposition during term of opposition